Rallybio Corp

For the period ended Sep 30, 2024. Filed Nov 7, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 7, 2024

RLYB$15.76+0.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss

Condensed Consolidated Statements of Operations and Comprehensive Loss

	FOR THE THREE MONTHS ENDED SEPTEMBER 30,		FOR THE NINE MONTHS ENDED SEPTEMBER 30,
(in thousands, except share and per share amounts)	2024	2023	2024	2023
Revenue:
Collaboration and license revenue	$299	$—	$598	$—
Total revenue	299	—	598	—
Operating expenses:
Research and development	8,240	13,288	34,122	37,620
General and administrative	4,125	6,075	15,364	20,200
Total operating expenses	12,365	19,363	49,486	57,820
Loss from operations	(12,066)	(19,363)	(48,888)	(57,820)
Other income:
Interest income	986	1,545	3,405	4,699
Other income	251	92	561	227
Total other income, net	1,237	1,637	3,966	4,926
Loss before equity in losses of joint venture	(10,829)	(17,726)	(44,922)	(52,894)
Loss on investment in joint venture	637	648	1,809	1,428
Net loss	$(11,466)	$(18,374)	$(46,731)	$(54,322)
Net loss per common share, basic and diluted	$(0.26)	$(0.45)	$(1.08)	$(1.35)
Weighted-average common shares outstanding, basic and diluted	44,593,221	40,531,497	43,170,177	40,382,625
Other comprehensive loss:
Net unrealized gain (loss) on marketable securities	240	64	154	6
Other comprehensive gain (loss)	240	64	154	6
Comprehensive loss	$(11,226)	$(18,310)	$(46,577)	$(54,316)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.